Company intelligence / Profile preview
Alcon Inc.
Geneva, Switzerlandalcon.com ↗
- Ownership
- Public · ALC
- Employees
- ~25599
- Development stage
- Commercial
01
Overview
Alcon has a commercial portfolio of surgical and vision care products. Their pharmaceutical pipeline includes Acoltremon (AR-15512), which has completed positive Phase 3 trials for dry eye disease with plans to file an NDA in mid-2024[6][10].
- Therapeutic areas
- Ophthalmology
- Modalities
- Ophthalmic pharmaceuticalssurgical devicescontact lensesintraocular lenses
- Industry
- Biotech
02
Drug pipeline
89 assets88 more assets in the full pipeline.
03
Financials
- Market cap
- $37B
- Total revenue
- $10.4B
- Enterprise value
- $40.8B
Beyond the preview
Go deeper on Alcon Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alcon Inc..